Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.55 |
| ▸ | CCR6 | P51684 | 10/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | CCR7 | P32248 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607634 | 0.97 | CCR6 (0.55) | HCRTR1CCR6HCAR3DPP4CCR7 | |
| SCHEMBL15739645 | 0.93 | CCR6 (0.61) | HCRTR1CCR6HCAR3DPP4CCR7 | |
| SCHEMBL25526387 | 0.87 | HCRTR1 (0.48) | HCRTR1CCR6DPP4CCNKCCNA2 | |
| SCHEMBL3807921 | 0.86 | CCR6 (0.55) | HCRTR1CCR6DPP4CCR7 | |
| SCHEMBL13100471 | 0.86 | CCR6 (0.55) | HCRTR1CCR6DPP4CCR7CCNK | |
| SCHEMBL3328240 | 0.86 | MAPK1 (0.63) | HCRTR1CCR6DPP4CCR7CCNK | |
| Hydrochloric Acid SCHEMBL381811 | 0.84 | MAPK1 (0.62) | HCRTR1CCR6DPP4CCR7 | |
| Hydrochloric Acid SCHEMBL30284852 | 0.84 | MAPK1 (0.62) | HCRTR1CCR6DPP4CCR7 | |
| Hydrochloric Acid SCHEMBL2418145 | 0.84 | MAPK1 (0.62) | HCRTR1CCR6DPP4CCR7 | |
| SCHEMBL20145185 | 0.84 | IL1B (0.53) | HCRTR1CCR6CCNKCDK2CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| CN-105164124-A | Compounds and compositions for treating parasitic diseases | NOVARTIS AG | 2015-12-16 | — | — | CN | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | HCRTR1 567/4885CCR6 2918/4885HCAR3 3579/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | HCRTR1 567/4885CCR6 2918/4885HCAR3 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.